Table 1.

Difference in cases and discounted costs, QALYs and cost-utility ratio with QIV versus TIV for all three models using FLOU inputs for Brazil.

	All models 1-year	FLORENCE lifetime
Cases avoided (N) (QIV vs TIV)
Vaccinated	0	−794,333
Influenza cases	145,169	8,650,885
Uncomplicated influenza 1st-line MA	74,509	5,015,454
NI treatmenta	0	0
Influenza complications	4986	416,479
Hospitalization	4986	416,479
Outpatient treatmenta	0	0
Influenza deaths	990	99,870
Without prior complicationsa	0	0
With prior complicationsa	990	99,870
Costs avoided (R$) (QIV vs TIV), 5% disc
Total vaccination costs	−145,682,900	−2,588,372,448
Vaccine price	−145,682,900	−2,588,216,523
Administration	0	−155,925
Uncomplicated influenza treatment	745,089	12,574,131
NI treatmenta	0	0
Antibioticsa	0	0
Medical visits	745,089	12,574,131
Inpatient complication treatment	5,371,315	97,664,516
GP visita	0	0
Hospitalizations	5,371,315	97,664,516
Outpatient complication treatmenta	0	0
Total costs	−139,566,496	−2,478,133,802
(QA)LYs gained (QIV vs TIV), 5% disc
LYs gainedb	8582	137,674
LYs gained during time horizonb	0	NA
LYs gained from deaths avoidedb	8582	NA
QALYs gainedb	6832	110,188
Baseline utilitiesb	0	101,382
From influenza avoided	310	5146
From hospitalization avoided	50	890
From outpatient treatment avoideda	0	0
From deaths avoidedb	6472	NA
Cost per LY gainedb	16,263	18,000
Cost per QALY gainedb	20,428	22,490

QIV vs TIV, quadrivalent versus trivalent influenza vaccine; MA, medical advice; NI, neuraminidase inhibitors; GP, general practitioner; LY, life-year; QALY, quality-adjusted life-year; NA, not applicable; disc, discounted.

^aNot applicable in FLOU.

^bNot applicable in FLORENCE 1-year.